Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl disaccharide—in patients with stage III and stage IV chronic kidney disease (CKC).
According to Revelation, several study data sets are expected during Q3, 2025, including safety standards, changes in hematologic parameters, in vitro evaluation, and multiple biomarkers of activity.
In a statement, James Rolke, CEO of Revelation, commented, “We thank our investigator and participants for the rapid completion of dosing. We are looking forward to sharing the study data shortly, and engaging the FDA to discuss future clinical development and approval pathways later this year.”
